Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Systematic exploration of protein conformational space using a Distance Geometry approach.

Malliavin TE, Mucherino A, Lavor C, Liberti L.

J Chem Inf Model. 2019 Aug 23. doi: 10.1021/acs.jcim.9b00215. [Epub ahead of print]

PMID:
31442036
2.

Minimal NMR distance information for rigidity of protein graphs.

Lavor C, Liberti L, Donald B, Worley B, Bardiaux B, Malliavin TE, Nilges M.

Discrete Appl Math. 2019 Mar 15;256:91-104. doi: 10.1016/j.dam.2018.03.071. Epub 2018 Apr 26.

3.

Revisiting racial differences in ESRD due to ADPKD in the United States.

Murphy EL, Dai F, Blount KL, Droher ML, Liberti L, Crews DC, Dahl NK.

BMC Nephrol. 2019 Feb 14;20(1):55. doi: 10.1186/s12882-019-1241-1.

4.

A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways.

Liberti L, McAuslane N, Stolk P, Breckenridge A, Leufkens H.

Ther Innov Regul Sci. 2018 Dec 6:2168479018813977. doi: 10.1177/2168479018813977. [Epub ahead of print]

PMID:
30522336
5.

The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways.

McAuslane N, Liberti L, Connelly P.

Clin Pharmacol Ther. 2019 Apr;105(4):935-942. doi: 10.1002/cpt.1315. Epub 2019 Jan 16. Review.

PMID:
30472729
6.

The Benefit-Risk Assessment of Medicines: Experience of a Consortium of Medium-Sized Regulatory Authorities.

McAuslane N, Leong J, Liberti L, Walker S.

Ther Innov Regul Sci. 2017 Sep;51(5):635-644. doi: 10.1177/2168479017696260. Epub 2017 Mar 30.

PMID:
30231684
7.

Acceptability of Mobile Phone-Based Nurse-Delivered Counseling Intervention to Improve HIV Treatment Adherence and Self-Care Behaviors Among HIV-Positive Women in India.

Duggal M, Chakrapani V, Liberti L, Satyanarayna V, Varghese M, Singh P, Ranganathan M, Chandra P, Reynolds NR.

AIDS Patient Care STDS. 2018 Sep;32(9):349-359. doi: 10.1089/apc.2017.0315.

PMID:
30179531
8.

Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.

Wang T, McAuslane N, Liberti L, Leufkens H, Hövels A.

Value Health. 2018 Jun;21(6):707-714. doi: 10.1016/j.jval.2017.11.003. Epub 2017 Dec 9.

9.

I have no peace of mind-psychosocial distress expressed by rural women living with HIV in India as part of a mobile health intervention-a qualitative study.

Chandra PS, Parameshwaran S, Satyanarayana VA, Varghese M, Liberti L, Duggal M, Singh P, Jeon S, Reynolds NR.

Arch Womens Ment Health. 2018 Oct;21(5):525-531. doi: 10.1007/s00737-018-0827-0. Epub 2018 Mar 17.

PMID:
29550891
10.

Accelerated approval of medicines: fit for purpose?

Breckenridge A, Liberti L.

Nat Rev Drug Discov. 2018 Jun;17(6):379-380. doi: 10.1038/nrd.2017.245. Epub 2018 Jan 5.

PMID:
29302066
11.

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

Allen N, Liberti L, Walker SR, Salek S.

Front Pharmacol. 2017 Jun 30;8:384. doi: 10.3389/fphar.2017.00384. eCollection 2017.

12.

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.

Liberti L, Bujar M, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H.

Front Pharmacol. 2017 Apr 3;8:161. doi: 10.3389/fphar.2017.00161. eCollection 2017.

13.

Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.

Allen N, Walker SR, Liberti L, Salek S.

Value Health. 2017 Mar;20(3):320-328. doi: 10.1016/j.jval.2016.10.014. Epub 2016 Dec 22.

14.

Factors related to drug approvals: predictors of outcome?

Liberti L, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H.

Drug Discov Today. 2017 Jun;22(6):937-946. doi: 10.1016/j.drudis.2017.03.003. Epub 2017 Mar 10. Review.

PMID:
28288783
15.

Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.

Allen N, Walker SR, Liberti L, Sehgal C, Salek MS.

CMAJ Open. 2016 Nov 3;4(4):E674-E678. doi: 10.9778/cmajo.20160006. eCollection 2016 Oct-Dec.

16.

Efficacy and implementation of an Internet psychoeducational program for teens with type 1 diabetes.

Whittemore R, Liberti LS, Jeon S, Chao A, Minges KE, Murphy K, Grey M.

Pediatr Diabetes. 2016 Dec;17(8):567-575. doi: 10.1111/pedi.12338. Epub 2015 Nov 26.

17.

An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.

Dörr P, Wadworth A, Wang T, McAuslane N, Liberti L.

Ther Innov Regul Sci. 2016 Nov;50(6):734-742. doi: 10.1177/2168479016655841. Epub 2016 Jul 18.

PMID:
30231740
18.

MAHILA: a protocol for evaluating a nurse-delivered mHealth intervention for women with HIV and psychosocial risk factors in India.

Reynolds NR, Satyanarayana V, Duggal M, Varghese M, Liberti L, Singh P, Ranganathan M, Jeon S, Chandra PS.

BMC Health Serv Res. 2016 Aug 4;16(a):352. doi: 10.1186/s12913-016-1605-1.

19.

Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities.

Liberti L, Breckenridge A, Hoekman J, Leufkens H, Lumpkin M, McAuslane N, Stolk P, Zhi K, Rägo L.

J Public Health Policy. 2016 Aug;37(3):315-333. doi: 10.1057/jphp.2016.8. Epub 2016 Mar 10.

PMID:
26961261
20.

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S.

Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Review.

21.

Costs of Development and Maintenance of an Internet Program for Teens with Type 1 Diabetes.

Grey M, Liberti L, Whittemore R.

Health Technol (Berl). 2015 Jul;5(2):127-133.

22.

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.

Liberti L, Stolk P, McAuslane JN, Schellens J, Breckenridge AM, Leufkens H.

Oncologist. 2015 Jun;20(6):683-91. doi: 10.1634/theoncologist.2014-0297. Epub 2015 May 6.

23.

Adaptive licensing and facilitated regulatory pathways: A survey of stakeholder perceptions.

Liberti L, Stolk P, McAuslane N, Somauroo A, Breckenridge AM, Leufkens HG.

Clin Pharmacol Ther. 2015 Nov;98(5):477-9. doi: 10.1002/cpt.140. Epub 2015 Jun 30. Review. No abstract available.

PMID:
25877216
24.

An algorithm to enumerate all possible protein conformations verifying a set of distance constraints.

Cassioli A, Bardiaux B, Bouvier G, Mucherino A, Alves R, Liberti L, Nilges M, Lavor C, Malliavin TE.

BMC Bioinformatics. 2015 Jan 28;16:23. doi: 10.1186/s12859-015-0451-1.

25.

A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?

Walker S, McAuslane N, Liberti L, Leong J, Salek S.

Ther Innov Regul Sci. 2015 Jan;49(1):17-25. doi: 10.1177/2168479014547421.

PMID:
30222450
26.

Do HTA Processes Correlate With Reimbursement Recommendations?

Allen N, Lipska I, Liberti L, Salek MS.

Value Health. 2014 Nov;17(7):A797-8. doi: 10.1016/j.jval.2014.08.475. Epub 2014 Oct 26. No abstract available.

27.

Self-management as a mediator of family functioning and depressive symptoms with health outcomes in youth with type 1 diabetes.

Whittemore R, Liberti L, Jeon S, Chao A, Jaser SS, Grey M.

West J Nurs Res. 2014 Oct;36(9):1254-71. doi: 10.1177/0193945913516546. Epub 2013 Dec 19.

28.

Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies.

Liu LL, McAuslane N, Tzou MC, Chern HD, Liberti L, Ward M, Kang JJ.

Ther Innov Regul Sci. 2013 Nov;47(6):678-683. doi: 10.1177/2168479013494394.

PMID:
30235555
29.

Regulatory review: How do agencies ensure the quality of decision making?

Liberti L, McAuslane N, Patel P, Breckenridge A, Eichler HG, Peterson R.

Clin Pharmacol Ther. 2013 Sep;94(3):305-8. doi: 10.1038/clpt.2013.127.

PMID:
23963218
30.

A discrete search algorithm for finding the structure of protein backbones and side chains.

Sallaume S, Martins Sde L, Ochi LS, Da Silva WG, Lavor C, Liberti L.

Int J Bioinform Res Appl. 2013;9(3):261-70. doi: 10.1504/IJBRA.2013.053606.

PMID:
23649739
31.

Algorithm for parametric community detection in networks.

Bettinelli A, Hansen P, Liberti L.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Jul;86(1 Pt 2):016107. Epub 2012 Jul 13.

PMID:
23005491
32.

An internet coping skills training program for youth with type 1 diabetes: six-month outcomes.

Whittemore R, Jaser SS, Jeon S, Liberti L, Delamater A, Murphy K, Faulkner MS, Grey M.

Nurs Res. 2012 Nov-Dec;61(6):395-404. doi: 10.1097/NNR.0b013e3182690a29.

33.

Exploiting symmetry properties of the discretizable molecular distance geometry problem.

Mucherino A, Lavor C, Liberti L.

J Bioinform Comput Biol. 2012 Jun;10(3):1242009. doi: 10.1142/S0219720012420097.

PMID:
22809385
34.

A comparison of two internet programs for adolescents with type 1 diabetes: design and methods.

Grey M, Whittemore R, Liberti L, Delamater A, Murphy K, Faulkner MS.

Contemp Clin Trials. 2012 Jul;33(4):769-76. doi: 10.1016/j.cct.2012.03.012. Epub 2012 Mar 29.

35.

Seasonal trends in depressive symptoms in adolescents with type 1 diabetes.

Jaser SS, Dumser S, Liberti L, Hunter N, Whittemore R, Grey M; TeenCope Research Group.

Diabetes Res Clin Pract. 2012 May;96(2):e33-5. doi: 10.1016/j.diabres.2012.01.023. Epub 2012 Feb 8.

36.

Locally optimal heuristic for modularity maximization of networks.

Cafieri S, Hansen P, Liberti L.

Phys Rev E Stat Nonlin Soft Matter Phys. 2011 May;83(5 Pt 2):056105. Epub 2011 May 6.

PMID:
21728603
37.

Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters.

Walker S, Liberti L, McAuslane N, Levitan BS.

Clin Pharmacol Ther. 2011 Feb;89(2):179-82. doi: 10.1038/clpt.2010.290. Erratum in: Clin Pharmacol Ther. 2011 Jun;89(6):928. Clin Pharmacol Ther. 2012 Jan;91(1):150. Levitan, B S [added].

PMID:
21252937
38.

Column generation algorithms for exact modularity maximization in networks.

Aloise D, Cafieri S, Caporossi G, Hansen P, Perron S, Liberti L.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Oct;82(4 Pt 2):046112. Epub 2010 Oct 21.

PMID:
21230350
39.

Kinetics of UV-H₂O₂ advanced oxidation in the presence of alcohols: the role of carbon centered radicals.

Popov E, Mametkuliyev M, Santoro D, Liberti L, Eloranta J.

Environ Sci Technol. 2010 Oct 15;44(20):7827-32. doi: 10.1021/es101959y.

PMID:
20828206
40.

Modeling hydroxyl radical distribution and trialkyl phosphates oxidation in UV-H2O2 photoreactors using computational fluid dynamics.

Santoro D, Raisee M, Moghaddami M, Ducoste J, Sasges M, Liberti L, Notarnicola M.

Environ Sci Technol. 2010 Aug 15;44(16):6233-41. doi: 10.1021/es1000962.

PMID:
20704221
41.

Loops and multiple edges in modularity maximization of networks.

Cafieri S, Hansen P, Liberti L.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Apr;81(4 Pt 2):046102. Epub 2010 Apr 2.

PMID:
20481781
42.

Edge ratio and community structure in networks.

Cafieri S, Hansen P, Liberti L.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Feb;81(2 Pt 2):026105. Epub 2010 Feb 17.

PMID:
20365629
43.

A pilot study of chromium picolinate for weight loss.

Yazaki Y, Faridi Z, Ma Y, Ali A, Northrup V, Njike VY, Liberti L, Katz DL.

J Altern Complement Med. 2010 Mar;16(3):291-9. doi: 10.1089/acm.2009.0286.

44.

Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.

Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S.

Clin Pharmacol Ther. 2010 Jan;87(1):27-31. doi: 10.1038/clpt.2009.179.

PMID:
20019699
45.

Effects of coping skills training in school-age children with type 1 diabetes.

Grey M, Whittemore R, Jaser S, Ambrosino J, Lindemann E, Liberti L, Northrup V, Dziura J.

Res Nurs Health. 2009 Aug;32(4):405-18. doi: 10.1002/nur.20336.

46.

Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study.

Ali A, Njike VY, Northrup V, Sabina AB, Williams AL, Liberti LS, Perlman AI, Adelson H, Katz DL.

J Altern Complement Med. 2009 Mar;15(3):247-57. doi: 10.1089/acm.2008.0410.

47.

Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.

Walker S, McAuslane N, Liberti L, Salek S.

Clin Pharmacol Ther. 2009 Mar;85(3):241-6. doi: 10.1038/clpt.2008.277.

PMID:
19223879
48.

The role of weathering on fly ash charge distribution during triboelectrostatic beneficiation.

Cangialosi F, Notarnicola M, Liberti L, Stencel J.

J Hazard Mater. 2009 May 30;164(2-3):683-8. doi: 10.1016/j.jhazmat.2008.08.050. Epub 2008 Aug 23.

PMID:
18819747
49.

Evaluating the impact of mobile telephone technology on type 2 diabetic patients' self-management: the NICHE pilot study.

Faridi Z, Liberti L, Shuval K, Northrup V, Ali A, Katz DL.

J Eval Clin Pract. 2008 Jun;14(3):465-9. doi: 10.1111/j.1365-2753.2007.00881.x. Epub 2008 Mar 24.

PMID:
18373577
50.

Wastewater disinfection by peracetic acid: assessment of models for tracking residual measurements and inactivation.

Santoro D, Gehr R, Bartrand TA, Liberti L, Notarnicola M, Dell'Erba A, Falsanisi D, Haas CN.

Water Environ Res. 2007 Jul;79(7):775-87.

PMID:
17710922

Supplemental Content

Loading ...
Support Center